Bioimmunoradiotherapy (BIR) With Concurrent Avelumab, Cetuximab and Radiotherapy as First Line Treatment in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. A Feasibility Study in Patients Unfit for Cisplatin
Phase of Trial: Phase I
Latest Information Update: 10 Mar 2017
At a glance
- Drugs Avelumab (Primary) ; Cetuximab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 15 Dec 2016 Status changed from not yet recruiting to recruiting.
- 06 Dec 2016 Planned initiation date changed from 1 Nov 2016 to 1 Dec 2016.
- 03 Nov 2016 Planned initiation date changed from 1 Oct 2016 to 1 Nov 2016.